Equities

IPCA Laboratories Ltd

IPCALAB:NSI

IPCA Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,454.35
  • Today's Change4.60 / 0.32%
  • Shares traded597.20k
  • 1 Year change+56.89%
  • Beta0.4030
Data delayed at least 15 minutes, as of Sep 19 2024 11:26 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 16-Sep-24
Select bar for recommendation details.
Recommendations16-Sep-24
Buy2
Outperform4
Hold2
Sell4
Strong Sell1

Share price forecast in INR

The 13 analysts offering 12 month price targets for IPCA Laboratories Ltd have a median target of 1,350.00, with a high estimate of 1,563.00 and a low estimate of 951.00. The median estimate represents a -7.46% decrease from the last price of 1,458.75.
High7.1%1,563.00
Med-7.5%1,350.00
Low-34.8%951.00

Dividends

In 2024, IPCA Laboratories Ltd reported a dividend of 4.00 INR, equaling last years dividend. The 9 analysts covering the company expect dividends of 5.36 INR for the upcoming fiscal year, an increase of 34.03%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in INR

On Aug 13, 2024, IPCA Laboratories Ltd reported 1st quarter 2025 earnings of 7.58 per share. This result exceeded the 5.00 expectation of the one analyst covering the company and exceeded last year's 1st quarter results by 18.07%.
Average growth rate+42.19%
IPCA Laboratories Ltd reported annual 2024 earnings of 21.57 per share on May 29, 2024.
Average growth rate+8.89%
More ▼

Revenue history & estimates in INR

Ipca Laboratories Limited had 1st quarter 2025 revenues of 20.93bn. This missed the 21.62bn consensus estimate of the 7 analysts following the company. This was 31.81% above the prior year's 1st quarter results.
Average growth rate+7.75%
Ipca Laboratories Limited had revenues for the full year 2024 of 77.05bn. This was 23.39% above the prior year's results.
Average growth rate+13.66%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.